Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection
| Author | Mohssen Nassiri Toosi | en |
| Author | Mohammad Sadeghi Hassanabadi | en |
| Issued Date | 2004-09-30 | en |
| Abstract | Hearing loss has been reported on interferons therapy. Combination therapy of pegylated (PEG)-IFN alfa2a plus ribavirin is the current optimal therapy for hepatitis C infection. PEG-INF side effect profile is reported similar in different studies, but with the increasing long-term use of PEG-INF several new adverse effects have been recognized. However, hearing loss has only been recorded once. We report a case of sensorineural hearing loss occurring in a patient with chronic hepatitis C treated with PEG-IFN plus ribavirin and recovered partially one month after the discontinuation of PEG-INF. The ototoxicity would be more serious with the use of PEG-INF. Patients on therapy with this drug should be monitored for auditory disability. The ototoxicity is reversible with discontinuation of drug if the diagnosis is made early in the course. | en |
| DOI | https://doi.org/ | en |
| URI | https://brieflands.com/journals/hepatmon/articles/70572 | en |
| Keyword | Article | en |
| Publisher | Brieflands | en |
| Title | Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection | en |
| Type | Case Report | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 70572-pdf.pdf
- Size:
- 27.38 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF